NDA 021120 · Serono INC
Novantrone
Mitoxantrone Hydrochloride · Injection
Priority reviewDiscontinuedLast checked: Nov 20, 2026Latest source record: Oct 13, 2000 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Oct 13, 2000
Approved uses
1
Original approval plus efficacy supplements
Registered trials
415
92 Phase 3, 49 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 13, 2000 Original approval · Type 6 - New Indication (no longer used) · priority review LetterLabelReview
1 products under this application
- NOVANTRONE · MITOXANTRONE HYDROCHLORIDE EQ 2MG BASE/ML · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Mitoxantrone" as an intervention, any sponsor and status, largest first.
- Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast CancerPivotal-lookingCompleted
University Hospital BirminghamAcademic, hospital or other
NCT00003893 · 2,250 participants (planned) · Start Jul 1998
Drug: CMF regimen; cyclophosphamide and 6 more · For: Breast Cancer
Sites: Birmingham, United Kingdom
- Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid LeukemiaPivotal-lookingCompleted
Medical Research CouncilGovernment (non-federal)
NCT00003436 · 2,000 participants (planned) · Start Jul 1998
Drug: amsacrine; asparaginase and 6 more · For: Leukemia; Myelodysplastic Syndromes
Sites: Manchester, United Kingdom
- Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid LeukemiaPivotal-lookingStatus unknown
Medical Research CouncilGovernment (non-federal)
NCT00002658 · 2,000 participants (planned) · Start Jan 1994
Drug: filgrastim; amsacrine and 8 more · For: Leukemia; Neutropenia
Sites: Cardiff, United Kingdom
- Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromePivotal-lookingCompleted
Leukemia Research FundAcademic, hospital or other
NCT00005823 · 2,000 participants (planned) · Start Dec 1998
Drug: cytarabine; daunorubicin hydrochloride and 7 more · For: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Sites: Birmingham, United Kingdom; London, United Kingdom; Cardiff, United Kingdom
- Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT01371981 · 1,645 participants · Start Jul 6, 2011 · Primary completion Mar 31, 2019
Drug: Asparaginase; Bortezomib and 5 more · For: Acute Myeloid Leukemia; Leukemia Cutis; Myeloid Neoplasm and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 220 sites in all
- Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous LeukemiaPivotal-lookingStatus unknown
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00002549 · 1,520 participants (planned) · Start Nov 1993
Drug: filgrastim; busulfan and 7 more · For: Leukemia
Sites: Innsbruck, Austria; Antwerp, Belgium; Bruges, Belgium · 75 sites in all
- Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's LymphomaPivotal-lookingStatus unknown
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00003728 · 1,500 participants (planned) · Start Dec 1998 · Primary completion May 2008
Drug: asparaginase; cyclophosphamide and 15 more · For: Leukemia; Lymphoma
Sites: Antwerp, Belgium; Brussels, Belgium; Ghent, Belgium · 23 sites in all
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT04293562 · 1,400 participants (planned) · Start Jul 21, 2020 · Primary completion Jun 30, 2029
Drug: Asparaginase Erwinia chrysanthemi; Cytarabine and 9 more · For: Acute Myeloid Leukemia
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 206 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Tannock IF, de Wit R, Berry WR, et al. · N Engl J Med 2004 · Clinical Trial, Clinical Trial, Phase III
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS, Oudard S, Ozguroglu M, et al. · Lancet 2010 · Clinical Trial, Phase III, Comparative Study
- Mitoxantrone for multiple sclerosis.
Martinelli Boneschi F, Rovaris M, Capra R, et al. · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
- Mitoxantrone: a novel anthracycline derivative.
Koeller J, Eble M · Clin Pharm 1988 · Clinical Trial, Review
- Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.
Eisenberger M, Hardy-Bessard AC, Kim CS, et al. · J Clin Oncol 2017 · Clinical Trial, Phase III, Multicenter Study
- [New anthracyclines].
Ogawa M, Ariyoshi Y · Gan To Kagaku Ryoho 1993 · Clinical Trial, English Abstract
Sponsor: Serono INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.